Skip to main content
. 2021 Jan 26;77(Pt 2):237–248. doi: 10.1107/S2059798320016125

Figure 1.

Figure 1

The small-molecule inhibitor ML162 targeting Sec46 of human GPX4. The (S)-enantiomer (stereocenter depicted in green, covalent warhead α-­chloroacetamide in blue) is shown. The postulated product of the covalent reaction with Sec46 of GPX4WT is shown on the right.